Janssen’s Invokana became the only medicine in nearly 20 years and the first diabetes medicine ever to demonstrate a reduction in progression to end-stage renal failure in T2D patients with CKD.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2019-04-15 12:32:352019-04-15 13:02:44Janssen Presents Landmark Data From Invokana Study